S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial

摘要

To our knowledge, the ACTS-CC 02 trial is the first randomized phase III study to evaluate the therapeutic usefulness of oxaliplatin-based adjuvant chemotherapy in patients with high-risk stage III colon cancer. SOX (S-1 plus oxaliplatin) was not shown to be superior to UFT/LV (uracil-tegafur plus leucovorin) in term of disease-free survival. However, the oxaliplatin-based regimen was suggested to be more effective in advanced disease, such as N2b.